Live
FierceBiotechAstraZeneca plucks preclinical EGFR degrader from Pinetree for $25MNovo NordiskIs Novo Nordisk's GLP-1 dominance fading after Lilly's clinical wins? - MSNSiemens HealthineersSiemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Botto - AD HOC NEWSBioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPOInsilico MedicineInsilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy - BioPharma APACMedtronicMedtronic Advances First Clinical Cases with Stealth AXiS™ Surgical System, Demonstrating the Power of Connected Smart Ecosystems Across Neurosurgery - Orthopedics This WeekBoston ScientificBoston Scientific Corporation (BSX): Stephen Mandel Opens New Position in Medical Device Firm - Yahoo Finance10x Genomics NewsVanguard holds 6.17M shares of 10X Genomics (NASDAQ: TXG), 5.24% stake - Stock Titan10x Genomics Blog10x Genomics investors can watch management at a May 13 BofA chat - Stock Titan10x Genomics News10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - PR Newswire10x Genomics Blog10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - Yahoo Finance UKFierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
Charles River 9. Feb. 2026

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays - News-Medical

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays - News-Medical

Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.